Stay updated on HMPL-523 Clinical Trial in B-cell Neoplasms
Sign up to get notified when there's something new on the HMPL-523 Clinical Trial in B-cell Neoplasms page.

Latest updates to the HMPL-523 Clinical Trial in B-cell Neoplasms page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe record presents details of a completed Phase I study of HMPL-523 for relapsed or refractory mature B-cell neoplasms, including eligibility criteria, study locations, treatment design, and outcome measures.SummaryDifference40%

- Check18 days agoChange DetectedThe site footer now identifies the ClinicalTrials.gov version as v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check25 days agoChange DetectedA notice appears above the error page announcing NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” under Executive Order 14434.SummaryDifference1%

- Check32 days agoChange DetectedThe footer revision changed from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer revision identifier was updated from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the previous study content with a minimal error screen and basic site navigation.SummaryDifference17%

Stay in the know with updates to HMPL-523 Clinical Trial in B-cell Neoplasms
Enter your email address, and we'll notify you when there's something new on the HMPL-523 Clinical Trial in B-cell Neoplasms page.